



Canadian Paediatric Surveillance Program

New Study and One-Time Survey Opportunities

The opportunity

- Benefit from the CPSP's well-established, timely, cost-effective, and internationally recognized surveillance platform.
- The CPSP is effective at monitoring low-frequency, high-impact diseases and conditions encountered by general paediatricians and paediatric subspecialists.

Track record

- The average monthly response rate from approximately 2,500 paediatricians is 80%.
- The average detailed questionnaire response rate varies from 80% to 90%.

Themes of interest

Including examples of successful CPSP studies

- Rare diseases (including genetic, metabolic, or rare acquired conditions)
 - Congenital myotonic dystrophy
 - Medium-chain acyl-coenzyme A dehydrogenase deficiency
- Rare complications of more common diseases
 - Adrenal suppression with glucocorticoid therapy
 - Health hazards related to the consumption of energy drinks
- Emerging infections
 - Congenital Zika syndrome
 - Lyme disease
- Threats to public health and safety
 - Adverse events related to exposure to laundry detergent pods
 - All-terrain vehicle severe injury and death

Study success factors

- A study or condition with an incidence of less than 500 cases per year
- A multidisciplinary study team, with national representation
- Local champions who encourage study reporting at their institutions

Study impact

Knowledge translation: Studies have been published in high-impact, peer-reviewed journals; the CPSP is well known and recognized by prominent editorial boards.

Public health policies and legislation: Results have informed the total ban on baby walkers and the promotion of booster seats to prevent lap-belt syndrome.

Professional medical guidelines: Results have informed guidelines such as the Canadian Paediatric Society position statement on neonatal hyperbilirubinemia and a practice point on pulse oximetry screening.

Public health promotion and education: Results have informed efforts to prevent vitamin D deficiency rickets and the use of e-cigarettes in those under the legal age to use conventional tobacco products.

“For the past 20 years, the CPSP has been an important collaborative asset for research, health policy development, and the active surveillance of less common paediatric disorders. The hundreds of Canadian paediatricians and paediatric subspecialists who participate monthly in the program ensure that the CPSP is an effective way to foster continuing medical education on a wide spectrum of clinical conditions that might otherwise go largely unrecognized.”

Bryce Larke, MD, Professor of Pediatrics, University of Alberta, Edmonton, 1975–2001; Chief Medical Officer of Health, Whitehorse, Yukon, 2001–2008; CPSP Steering Committee member, 2004–2010



For more information, please call us at 613-526-9397 ext. 239, e-mail cpsp@cps.ca or visit www.cpsp.cps.ca.